These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23887294)

  • 1. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
    Krasinskas AM; Chiosea SI; Pal T; Dacic S
    Mod Pathol; 2014 Feb; 27(2):262-70. PubMed ID: 23887294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.
    Wang CX; Liu B; Wang YF; Zhang RS; Yu B; Lu ZF; Shi QL; Zhou XJ
    Int J Clin Exp Pathol; 2014; 7(3):1266-74. PubMed ID: 24696747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
    Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
    Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
    Girard N; Deshpande C; Azzoli CG; Rusch VW; Travis WD; Ladanyi M; Pao W
    Chest; 2010 Jan; 137(1):46-52. PubMed ID: 19376842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
    Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
    Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.
    Dacic S; Shuai Y; Yousem S; Ohori P; Nikiforova M
    Mod Pathol; 2010 Feb; 23(2):159-68. PubMed ID: 19855375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.
    Ritterhouse LL; Vivero M; Mino-Kenudson M; Sholl LM; Iafrate AJ; Nardi V; Dong F
    Mod Pathol; 2017 Dec; 30(12):1720-1727. PubMed ID: 28776576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.
    Rekhtman N; Ang DC; Riely GJ; Ladanyi M; Moreira AL
    Mod Pathol; 2013 Oct; 26(10):1307-19. PubMed ID: 23619604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.
    Ichinokawa H; Ishii G; Nagai K; Kawase A; Yoshida J; Nishimura M; Hishida T; Ogasawara N; Tsuchihara K; Ochiai A
    Hum Pathol; 2013 Dec; 44(12):2636-42. PubMed ID: 24119562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
    Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
    Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of KRAS Mutations in Gastrointestinal Tract Adenocarcinomas Reveals Site-Specific Mutational Signatures.
    Wang L; Saeedi BJ; Mahdi Z; Krasinskas A; Robinson B
    Mod Pathol; 2023 Feb; 36(2):100014. PubMed ID: 36853786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.
    Raparia K; Villa C; Raj R; Cagle PT
    Arch Pathol Lab Med; 2015 Feb; 139(2):189-93. PubMed ID: 24694341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
    Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
    Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
    Dogan S; Shen R; Ang DC; Johnson ML; D'Angelo SP; Paik PK; Brzostowski EB; Riely GJ; Kris MG; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2012 Nov; 18(22):6169-77. PubMed ID: 23014527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.